EXPERIENCE OF TREATMENT WITH LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (RVD) IN THE FIRST LINE IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA IN THE HOSPITALS OF ARAGON AND THE PROVINCE OF SORIA

被引：0
|
作者：
Yus Cebrian, F. [1 ]
Paul Vidaller, P. J. [1 ]
Romero Quezada, L. L. [1 ]
Perella Arnal, M., I [1 ]
Campuzano Saavedra, V [2 ]
Sancho Val, L., I [3 ]
Gonzalez Gomez, N. [4 ]
Marco Amigot, J. J. [5 ]
Murillo Flores, I. M. [5 ]
Carrasco Baraja, V [6 ]
Godoy Molias, A. C. [7 ]
Paricio Moreno, M. [3 ]
Malo Yague, M. [8 ]
Delgado Beltran, M. P. [7 ]
Aguilar Franco, C. [2 ]
Palomera Bernal, L. R. [9 ]
机构：
[1] Hosp Barbastro, Huesca, Huesca, Spain
[2] Hosp Santa Barbara, Puertollano, Spain
[3] Hosp Alcaniz, Alcaniz, Teruel, Spain
[4] Hosp Obispo Polanco, Teruel, Spain
[5] Hosp San Jorge, Huesca, Spain
[6] Hosp Royo Villanova, Zaragoza, Spain
[7] Hosp Miguel Servet, Zaragoza, Spain
[8] Hosp Ernest Lluch, Zaragoza, Spain
[9] Hosp Clin Lozano Blesa, Zaragoza, Spain
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PC-013
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [31] Bortezomib thalidomide dexamethasone as first-line treatment in Newly Multiple Myeloma Patients in Peru
    Vasquez, Jule
    Castillo, Claudia
    Lopez, Naty
    Quintana, Shirley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S248 - S248
  • [32] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [33] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    Blood Cancer Journal, 13
  • [34] Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone
    Huo, Zhongjun
    Chen, Fang
    Liu, Ping
    Luo, Zimian
    CANCER MEDICINE, 2023, 12 (03): : 2937 - 2944
  • [35] Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China
    Xu, Jingyu
    Yan, Wenqiang
    Fan, Huishou
    Liu, Jiahui
    Du, Chenxing
    Deng, Shuhui
    Sui, Weiwei
    Xu, Yan
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S159 - S159
  • [36] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
  • [37] Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma
    Inyang, Eno
    Aktas-Samur, Anil
    Munshi, Nikhil C.
    Leblebjian, Hour
    BLOOD, 2021, 138
  • [38] Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.
    Ailawadhi, Sikander
    Lee, Hans Chulhee
    Omel, Jim
    Toomey, Kathleen
    Hardin, James W.
    Gasparetto, Cristina
    Jagannath, Sundar
    Rifkin, Robert M.
    Durie, Brian G.
    Narang, Mohit
    Terebelo, Howard R.
    Wagner, Lynne, I
    Dhalla, Mazaher
    He, Mia
    Srinivasan, Shankar
    Joshi, Prashant Ramesh
    Robinson, Suzanne
    Abonour, Rafat
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy
    Odikadze, Levani
    Joseph, Nisha
    Schmidt, Timothy M.
    Heffner, Leonard
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Gupta, Vikas A.
    Boise, Lawrence H.
    Jaye, David L.
    Lonial, Sagar
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    BLOOD, 2018, 132
  • [40] Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)
    Inyang, Eno
    Munshi, Nikhil C.
    Aktas-Samur, Anil
    Leblebjian, Houry
    BLOOD, 2020, 136
12345